BetterLife Pharma Inc. (BETRF) Financial Analysis and Rating

Comparison Analysis Based on SEC Data

Company Name BetterLife Pharma Inc.
Industry (SIC) 2834 - Pharmaceutical Preparations
Assets as of 1/31/2019 $8,596 thousand
Analyzed report 1/31/2018 (filed 5/01/2018)

Year:
20172018

Financial Position and Performance
Annual | Quarterly

Compared with 2017 industry ratios Change during the year

worse
improved
Compared with all listed companies

much worse

Compare with a competitor

Financial Ratios Benchmarking

Financial Ratio Comparison of company ratios for 2017
with industry ratios
(28 - Chemicals And Allied Products) 		with all listed companies
Solvency Ratios
Debt ratio 
1.12
0.51
1.12
0.63
Debt-to-equity ratio 
Negative equity
Negative equity
Interest coverage ratio 
-38.31
-7.26
-38.31
1.84
Liquidity Ratios
Current Ratio 
0.71
2.71
0.71
1.56
Cash Ratio 
0.31
1.59
0.31
0.42
Profitability Ratios
Profit margin 
-49.1%
-69.7%
-49.1%
2.6%
ROE (Return on equity), after tax 
Negative equity
Negative equity
ROA (Return on assets) 
-46.9%
-41.9%
-46.9%
0.5%
Activity Ratios
Asset turnover (days) 
382
1072
382
635
Resulting score -0,9 -1,3

Year:
20172018

Additional Ratios (not used in score calculation)

Financial Ratio Comparison of company ratios for 2017
with industry ratios
(28 - Chemicals And Allied Products) 		with all listed companies
Profitability Ratios
Gross margin 
-22.9%
46.9%
-22.9%
41.7%
Operating margin (Return on sales) 
-425.1%
-27%
-425.1%
6.4%
Activity Ratios
EBIT  $(1)M
EBITDA  $(1)M

Auditor's Conclusion

We have performed a comparative analysis of the balance sheet and income statement of BetterLife Pharma Inc. (hereafter – the "Company") for the year 2017 as filed with the U.S. Securities and Exchange Commission (SEC). The primary business activity of the Company is "Pharmaceutical Preparations" (SIC code 2834). In our analysis, we compared the key financial ratios of the Company with the average (median) values of those ratios calculated for the Company's specific industry sector and for all companies. The averages were calculated using data from 2017 financial statements filed with the SEC through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). By comparing each of the eleven key metrics to the median, we have reached an overall conclusion about the quality of the Company's financial condition. All calculations and conclusions were performed using software and methodologies developed by ReadyRatios.

Based on our analysis of the Company's key financial ratios, we have determined the following. The financial condition of BetterLife Pharma Inc. in 2018 is worse than the typical financial condition of companies in the "Pharmaceutical Preparations" industry.

Compared to the averages for all industries, the Company shows even weaker results. The financial position of BetterLife Pharma Inc. is much worse than that of most listed companies that file financial statements with the U.S. Securities and Exchange Commission.

Financial Position and Performance History


More on BetterLife Pharma Inc.

Closest Competitors

Company USD ($), in Millions</